focus -WSS

focus

author：fashion 2025-09-03 09:28:16 - browse：8

Ionis Pharmaceuticals, a California biotech that has spearheaded the development of RNA-targeting medicines, announced on Tuesday that its drug against familial chylomicronemia syndrome, a rare and serious disease that prevents the body from breaking down fats, succeeded in a late-stage clinical trial.

The Phase 3 trial, dubbed Balance, enrolled 66 adults who were randomly divided into three groups and given a monthly injection of placebo or one of two doses of olezarsen, the company’s experimental drug. Treatment with the higher dose of the therapy significantly lowered triglycerides in the blood of those on the drug for six months compared to participants given placebo, though a lower dose did not have this effect. Participants on the high dose didn’t have any instances of painful inflammation of the pancreas, one of the disease’s most serious symptoms, while there were 11 such episodes among those on placebo.

Researchers reported that the treatment was also generally safe, with fewer adverse events among those on olezarsen than among the placebo group.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Three trends to watch in biotech in 2024

hotspot

WSS

Genentech weighs delaying cancer therapy after drug pricing law

GOP presidential candidates start declaring their loyalty

Three trends to watch in biotech in 2024

After John Oliver segment, STAT readers share their opioid

O'Shea Sibley was killed after expressing queer joy by voguing, activists say

An innovative path out of biotech’s “valley of death”

focus

focus

explore

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Iran moves toward freeing 5 American citizens who had been imprisoned, in rare deal

After affirmative action ruling, medical educators look to 'holistic review'

Iran moves toward freeing 5 American citizens who had been imprisoned, in rare deal

At least 13 dead in Texas as scorching temps continue

Who are the detained American citizens released from prison in Iran?

Activists slam private health insurers over coverage restrictions

What STAT readers think about the FDA and patient advocacy

Bright Health sells Medicare Advantage business to Molina

Some of the ways extreme heat will change life as we know it

hotspot

Who are the detained American citizens released from prison in Iran?

How to keep neuroscience’s past racism from being its future

Albert Bourla of Pfizer: worst biopharma CEO of 2023

Listen: Your guide to Wegovy's blockbuster heart study

Timeline: Special counsel's investigation into Trump's handling of classified documents

Three trends to watch in biotech in 2024

focus

focus

hotspot

focus